<DOC>
	<DOCNO>NCT02641093</DOCNO>
	<brief_summary>The purpose research study test safety benefit add pembrolizumab ( therapy activate immune system fight cancer ) standard care treatment head neck cancer . The standard care treatment include surgery follow radiation 6 week . Some patient may also receive cisplatin standard care week 6 week cancer find `` high risk '' . High risk include cancer completely remove ( positive margin ) cancer invade outer line lymph node .</brief_summary>
	<brief_title>Phase II Trial Adjuvant Cisplatin Radiation With Pembrolizumab Resected Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients eligible resection one follow 1 . Any T stage â‰¥ N2 disease ; 2 . T4 disease , N stage ; 3 . T3 Oral Cavity , N stage ; 4 . Clinical evidence extracapsular extension scan . Must willing undergo definitive resection neck dissection . Performance status 0 1 Eastern Cooperative Oncology Group Performance Scale . Adequate labs Appropriate staging imaging . Diagnosis immunodeficiency receive systemic steroid therapy immunosuppressive therapy within 7 day prior plan first dose trial treatment . Nasopharyngeal sinonasal carcinoma Confirmed metastatic disease Human Papillomavirus ( HPV ) + disease oropharynx Known history active tuberculosis ( TB ) , autoimmune disease , pneumonitis , infection , HIV , Hepatitis B , Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>